Skip to main content
Premium Trial:

Request an Annual Quote

uBiome Raises $83M in Series C Round

NEW YORK (GenomeWeb) – uBiome announced today that it has raised $83 million in a Series C financing round, led by OS Fund.

Other participants included 8VC, Y Combinator, Denstu Ventures, and additional new and existing investors.

uBiome said it will use the funding it raised for several projects, including expanding its product portfolio; leveraging its microbiome database to expand into drug R&D using pre-existing patent assets and industry research; speeding up commercialization of SmartGut, SmartJane, Explorer and other clinical tests under development; and starting commercialization of biopharmaceutical molecules and live biotherapeutics.

uBiome integrates precision sequencing technology with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets.  

"This financing allows us to expand our product portfolio, increase our focus on patent assets, and further raise our clinical profile, especially as we begin to focus on commercialization of drug discovery and development of our patent assets," uBiome Cofounder and CEO Jessica Richman said in a statement.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.